AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
NuSkin Enterprises, Inc.
XNYS · usd
SIC 5122 · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
FIGI BBG001S988X5
4.79▼ 0.13 (-2.64%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
4.92
Day's Range
4.72 – 4.90
52-Week Range
4.45 – 11.67
Volume
318.2K
Avg Volume
463.0K
Share Statistics
Shares Outstanding
Employees
8,600
Exchange
XNYS
Listed
1996-11-22
Share count as of July 31, 2026

NuSkin Enterprises, Inc. (NUS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about NuSkin Enterprises, Inc. (NUS)
What is NuSkin Enterprises, Inc.'s Market Cap?
NuSkin Enterprises, Inc.'s Market Cap is $233.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NUSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-17.1%-12.0%-16.9%-15.3%
Cost of sales
Gross profit
% of revenue68.2%66.9%70.7%70.5%
Operating expenses:
Selling expenses
General and administrative expenses
Impairment expenses——
Total operating expenses
% of revenue86.7%65.6%64.5%64.5%
Operating income (loss)
% of revenue-18.5%1.3%6.3%5.9%
Interest expense
Gain on sale of business
Other income (expense), net
Income (loss) before provision for income taxes
Provision for income taxes
Net income (loss)
% of revenue-78.0%0.6%3.9%4.7%
Basic (in Dollars per share)
Diluted (in Dollars per share)